The research, published in BMC Pediatrics, followed 81 patients aged 1 to 18 years over a six-month period. The cohort included 36 children with maple syrup urine disease, a disorder of branched-chain amino acid metabolism; 30 with methylmalonic or propionic acidemia, two related organic acidemias; 6 with isovaleric acidemia; and 9 with urea cycle disorders, which impair the body’s ability to convert waste nitrogen into urea for excretion. At the start of the study and again six months later, the team collected detailed anthropometric measurements, three-day dietary records analyzed with the BeBiS 8.2 nutrition software, and plasma amino acid profiles, alongside metabolic control parameters such as ammonia levels and acid-base status drawn from patient files.

The headline finding is sobering. Among children with maple syrup urine disease, 47.2 percent were stunted and 36 percent were underweight at baseline, and six months later the figures remained essentially unchanged at 44.4 percent and 52.2 percent respectively. In the methylmalonic and propionic acidemia group, the situation actually worsened over the study window: the prevalence of underweight rose from 34.8 percent to 43.5 percent, while stunting climbed from 43.3 percent to 50 percent. Children with urea cycle disorders showed persistent stunting at a rate of 44.4 percent. Only the small isovaleric acidemia group maintained normal growth, a bright spot the authors note with caution given the limited number of patients involved.

What makes these numbers particularly troubling is that they occurred despite what appears, on paper, to be adequate nutrition. Total protein intake in the cohort met disease-specific guideline recommendations, and the protein-to-energy ratio, a key metric in metabolic dietetics that describes how much protein is delivered relative to total caloric intake, fell within recommended ranges. Yet when the researchers dissected the composition of that protein, a different picture emerged. Natural protein from ordinary foods remained insufficient across the groups, and in children with maple syrup urine disease, synthetic amino acid mixtures supplied up to 75 percent of total protein intake. These medical formulas, stripped of the amino acids the patients cannot metabolize, are the backbone of treatment, but the study suggests that heavy reliance on them may come at a cost.

That cost shows up in the blood. Chronic deficiencies of the essential amino acids isoleucine and valine were prominent in patients with maple syrup urine disease and in those with methylmalonic and propionic acidemia. This is a known hazard of amino acid therapy: because the synthetic mixtures must exclude or severely limit the offending amino acids, patients can easily tip into deficiency of other essential amino acids if the formulation and natural protein allowance are not finely tuned. Isoleucine and valine are indispensable for protein synthesis, and chronically low plasma levels could plausibly constrain linear growth, muscle development, and overall nutritional status in growing children.

Dietary quality beyond protein also emerged as a consistent weakness. Intake of polyunsaturated fatty acids, the omega-3 and omega-6 fats critical for brain development and inflammatory regulation, was inadequate in every disease group, as was dietary fiber. Restricted diets naturally limit food variety, and children who consume large fractions of their nutrition as formula often miss out on the whole grains, seeds, nuts, and oily fish that supply these micronutrients and macronutrients in a typical diet. The researchers suggest that this suboptimal dietary quality may be another contributing factor to the poor growth outcomes they documented.

One of the most intriguing results concerns acid-base status. In children with methylmalonic and propionic acidemia, blood pH showed a positive correlation with height-for-age Z-score, with a correlation coefficient of 0.410 and a p-value below 0.05. In plain terms, children whose blood was less acidic tended to be taller for their age. Organic acidemias are characterized by recurrent episodes of metabolic acidosis, in which acidic metabolites accumulate and lower blood pH, and chronic or repeated acidosis is known from other clinical contexts to suppress growth hormone signaling and bone mineralization. While a correlation cannot prove causation, the finding hints that more aggressive control of acid-base balance might be an underappreciated lever for improving growth in these patients. Notably, the protein-to-energy ratio showed no association with height-for-age Z-scores, suggesting that simply adjusting macronutrient proportions may not be enough to rescue growth.

The study also exposes a gap in the clinical infrastructure supporting these families. The authors found substantial variability among current disease-specific dietary guidelines, meaning that children with the same diagnosis may receive meaningfully different nutritional prescriptions depending on which protocol their center follows. For ultra-rare diseases where evidence is scarce and guidelines are often built on expert consensus rather than controlled trials, this inconsistency is understandable but consequential. The researchers argue that their findings underscore the need for standardized, evidence-based nutritional protocols developed through multi-center collaboration.

Methodologically, the study has both strengths and limitations worth noting. Its prospective design, with standardized anthropometry, dietary records, and plasma amino acid measurements at two time points, is more rigorous than the retrospective chart reviews that dominate the rare disease literature. The statistical approach, using Wilcoxon tests for paired comparisons and Spearman correlations for associations, is appropriate for the non-normally distributed data typical of nutritional studies. On the other hand, the six-month follow-up is short for assessing linear growth, which unfolds over years, and the small size of the isovaleric acidemia and urea cycle disorder subgroups limits the precision of conclusions for those diagnoses. The study was approved by the ethics committee of Gaziantep University Faculty of Medicine, with written informed consent obtained from participants and their parents, and it received no external funding.

For clinicians and families, the practical message is that growth impairment in organic acidemias and urea cycle disorders is not a sign of dietary non-compliance but a signal that current therapeutic strategies may be inherently insufficient. The authors call for close monitoring by a multidisciplinary metabolic team, including physicians, dietitians, and nurses, with attention to optimizing natural protein tolerance, correcting essential amino acid imbalances, supplementing polyunsaturated fatty acids and fiber, and vigilantly managing acid-base status. As newborn screening programs expand and more children with these disorders survive into adolescence and adulthood, the question of how to help them not just survive but thrive is becoming one of the defining challenges in the field of inherited metabolic disease.

Subject of Research: Dietary intake, metabolic control, and growth outcomes in children with organic acidemias and urea cycle disorders

Article Title: Dietary intake, metabolic control and growth in patients with organic acidemia and urea cycle disorders

Article References: Kumru Akin, B., Köşeci, B., Çiçek Türköz, E., Onenli Mungan, H. N., Keskin, M., & Gökmen Ozel, H. (2026). Dietary intake, metabolic control and growth in patients with organic acidemia and urea cycle disorders. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07722-5

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07722-5

Keywords: organic acidemia, urea cycle disorder, maple syrup urine disease, methylmalonic acidemia, propionic acidemia, isovaleric acidemia, dietary protein restriction, amino acid mixtures, stunting, metabolic acidosis, pediatric nutrition, growth impairment